Royalty Pharma RPRX Daraxonrasib — Research and development funding expense
Discontinued — last reported Q2 '25
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Royalty Pharma’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →
Ask your AI about Royalty Pharma's daraxonrasib — research and development funding expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Royalty Pharma's daraxonrasib — research and development funding expense?
- Royalty Pharma (RPRX) reported daraxonrasib — research and development funding expense of $250M in Q2 2025.
- What does daraxonrasib — research and development funding expense mean?
- The total amount of money invested by the company to support the research and development of the Daraxonrasib product candidate.
- How do you interpret daraxonrasib — research and development funding expense?
- An increase indicates higher investment in the asset's development, potentially signaling progress toward clinical milestones or expanded trial scope, while a decrease may suggest project completion, reprioritization, or cost-saving measures.
- How does daraxonrasib — research and development funding expense compare across companies?
- Comparable to R&D funding or development-stage investment metrics reported by other pharmaceutical royalty or venture-style investment firms that directly fund clinical trials for their portfolio assets.